MiddleBrook Pharmaceuticals' Nationwide Field Sales Force Hired

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has completed the hiring of its 271-person nationwide field sales force. The 271 territory managers comprising MiddleBrook�s field sales force will begin educating health care professionals on the benefits of MOXATAG (extended-release amoxicillin) Tablets, 775 mg � the first and only FDA-approved once-daily amoxicillin � on March 16, 2009.

Each member of MiddleBrook�s field sales force brings significant business-to-business sales or pharmaceutical experience and success to their role as a territory manager for MiddleBrook. The territories have been structured to maximize the 271-person field sales force�s ability to detail health care professionals nationwide, including pharmacists. The field force's efforts will be supported by a print media campaign targeted at health care professionals.

�We are delighted to have achieved another significant milestone in preparation for the launch of MOXATAG,� said John Thievon, president and CEO of MiddleBrook. �About 135 territory managers have already completed our comprehensive training program, and the remaining territory managers will be fully trained in advance of our professional launch date of March 16, 2009. The territory managers who have completed our training program are in the field now with KEFLEX� 750 mg patient starter samples talking to health care professionals about the advantages of our KEFLEX 750 mg product. Once we launch MOXATAG, all of our territory managers will detail MOXATAG and KEFLEX, and they will have MOXATAG patient starter samples as well.�

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We are currently developing a portfolio of anti-infective products utilizing our proprietary, prolonged-release pulsatile delivery technology, PULSYS�. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX�, the immediate-release brand of cephalexin, and MOXATAG� � the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

About MOXATAG:

MOXATAG (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of MOXATAG are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once- daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about MOXATAG, please visit www.middlebrookpharma.com.

About KEFLEX:

KEFLEX, immediate-release (cephalexin USP) capsules, is a first-generation cephalosporin antibiotic shown to be active against strains of both gram- positive and gram- negative aerobes in vitro and in clinical infections. KEFLEX is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on KEFLEX and prescribing information are available at www.middlebrookpharma.com/products_antibiotics/KEFLEX_antibiotics.aspx.

Forward-Looking Statements:

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential, " "estimate, " "will," "may," �predict,� "should, " "could, " "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in our Quarterly Report on Form 10-Q for the quarter ended Sept. 30, 2008, our Annual Report on Form 10-K for the year ended Dec. 31, 2007, and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. KEFLEX, MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., M1 (stylized), MOX-10, MOXAKIT, MOXATAG1 (stylized), MOXATAG, MOXATEN, MOX-PAK and PULSYS are our trademarks and have been registered in the U.S. Patent and trademark office or are the subject of pending U.S. trademarks applications. Each of the other trademarks, tradenames, or service marks appearing in this document belongs to the respective holder, As used herein, except as otherwise indicated by the context, references to �we,� � us,� �our,� � MiddleBrook,� or the �Company,� refer to MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.

Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Jun 2024 to Jul 2024